Analysts forecast that Zymeworks (NYSE:ZYME) will announce earnings of ($0.69) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Zymeworks’ earnings, with estimates ranging from ($0.69) to ($0.68). Zymeworks reported earnings per share of ($0.63) in the same quarter last year, which suggests a negative year-over-year growth rate of 9.5%. The business is scheduled to announce its next quarterly earnings results on Tuesday, August 14th.

On average, analysts expect that Zymeworks will report full year earnings of ($2.88) per share for the current year, with EPS estimates ranging from ($3.11) to ($2.64). For the next fiscal year, analysts forecast that the company will report earnings of ($2.41) per share, with EPS estimates ranging from ($3.06) to ($1.75). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Zymeworks.

Zymeworks (NYSE:ZYME) last released its quarterly earnings results on Wednesday, March 14th. The company reported $1.28 earnings per share (EPS) for the quarter. Zymeworks had a negative net margin of 30.41% and a negative return on equity of 16.07%. The business had revenue of $50.07 million for the quarter.

A number of equities research analysts have recently issued reports on ZYME shares. Raymond James started coverage on shares of Zymeworks in a report on Monday, March 19th. They set an “outperform” rating and a $18.00 price target on the stock. ValuEngine upgraded shares of Zymeworks from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Barclays upgraded shares of Zymeworks from an “underweight” rating to an “equal weight” rating and boosted their price target for the company from $8.00 to $15.00 in a report on Friday, May 11th. Ladenburg Thalmann started coverage on shares of Zymeworks in a report on Monday. They set a “buy” rating and a $25.00 price target on the stock. Finally, Canaccord Genuity upped their price objective on shares of Zymeworks from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Zymeworks presently has a consensus rating of “Buy” and an average price target of $17.82.

ZYME stock opened at $17.34 on Tuesday. Zymeworks has a 52-week low of $16.84 and a 52-week high of $17.58. The company has a market cap of $421.95 million and a PE ratio of -30.42.

A number of institutional investors have recently added to or reduced their stakes in the business. Perceptive Advisors LLC increased its stake in Zymeworks by 6.4% in the 4th quarter. Perceptive Advisors LLC now owns 777,497 shares of the company’s stock valued at $5,549,000 after buying an additional 46,729 shares during the period. PenderFund Capital Management Ltd. acquired a new position in Zymeworks in the 1st quarter valued at approximately $5,360,000. Finally, Stanley Laman Group Ltd. acquired a new position in Zymeworks in the 1st quarter valued at approximately $439,000. Hedge funds and other institutional investors own 8.69% of the company’s stock.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer.

Get a free copy of the Zacks research report on Zymeworks (ZYME)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zymeworks (NYSE:ZYME)

Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.